Abstract

Persistence of HIV in people living with HIV (PWH) on suppressive antiretroviral therapy (ART) has been linked to physiological mechanisms of CD4+ T cells. Here, in the same 37 male PWH on ART we measure longitudinal kinetics of HIV DNA and cell turnover rates in five CD4 cell subsets: naïve (TN), stem-cell- (TSCM), central- (TCM), transitional- (TTM), and effector-memory (TEM). HIV decreases in TTM and TEM but not in less-differentiated subsets. Cell turnover is ~10 times faster than HIV clearance in memory subsets, implying that cellular proliferation consistently creates HIV DNA. The optimal mathematical model for these integrated data sets posits HIV DNA also passages between CD4 cell subsets via cellular differentiation. Estimates are heterogeneous, but in an average participant’s year ~10 (in TN and TSCM) and ~104 (in TCM, TTM, TEM) proviruses are generated by proliferation while ~103 proviruses passage via cell differentiation (per million CD4). In simulations, therapies blocking proliferation and/or enhancing differentiation could reduce HIV DNA by 1-2 logs over 3 years. In summary, HIV exploits cellular proliferation and differentiation to persist during ART but clears faster in more proliferative/differentiated CD4 cell subsets and the same physiological mechanisms sustaining HIV might be temporarily modified to reduce it.

The authors used mathematical modeling of human data to study how HIV persists despite suppressive antiretroviral therapy. They found that when latently infected CD4+ T cells proliferate or differentiate, they can create HIV DNA and passage it into other subsets. More mature CD4 cell subsets then clear HIV DNA faster.

Details

Title
Estimating the contribution of CD4 T cell subset proliferation and differentiation to HIV persistence
Author
Reeves, Daniel B. 1   VIAFID ORCID Logo  ; Bacchus-Souffan, Charline 2 ; Fitch, Mark 3 ; Abdel-Mohsen, Mohamed 4   VIAFID ORCID Logo  ; Hoh, Rebecca 5 ; Ahn, Haelee 6 ; Stone, Mars 7   VIAFID ORCID Logo  ; Hecht, Frederick 6   VIAFID ORCID Logo  ; Martin, Jeffrey 8   VIAFID ORCID Logo  ; Deeks, Steven G. 5   VIAFID ORCID Logo  ; Hellerstein, Marc K. 3   VIAFID ORCID Logo  ; McCune, Joseph M. 9 ; Schiffer, Joshua T. 10   VIAFID ORCID Logo  ; Hunt, Peter W. 6 

 Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); University of Washington, Department of Global Health, Seattle, USA (GRID:grid.34477.33) (ISNI:0000 0001 2298 6657) 
 Vir Biotechnology, Inc, San Francisco, USA (GRID:grid.507173.7) 
 University of California, University Avenue and Oxford St, Department of Nutritional Sciences and Toxicology, Berkeley, USA (GRID:grid.468726.9) (ISNI:0000 0004 0486 2046) 
 The Wistar Institute, Philadelphia, USA (GRID:grid.251075.4) (ISNI:0000 0001 1956 6678) 
 University of California, Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of California San Francisco, Division of Experimental Medicine, Department of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 Vitalant Research Institute, San Francisco, USA (GRID:grid.418404.d) (ISNI:0000 0004 0395 5996) 
 University of California San Francisco School of Medicine, Epidemiology & Biostatistics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 Bill & Melinda Gates Foundation, HIV Frontiers, Global Health Accelerator, Seattle, USA (GRID:grid.418309.7) (ISNI:0000 0000 8990 8592) 
10  Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); University of Washington, Department of Allergy and Infectious Diseases, School of Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
Pages
6145
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2871490056
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.